Robert B. Nelson is listed as an executive officer and director on 3 SEC Form D filings by 1 issuer between Nov 2019 and Dec 2025: MindImmune Therapeutics, Inc. (Kingston, RI — pharmaceuticals — 2019–2025; $15.2M reported sold to 15 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Christopher O'Donnell (2 shared filings), Stevin Zorn (2 shared filings), Bradley Margus (1 shared filing), Diane Gooding (1 shared filing), Frank Menniti (1 shared filing) and 4 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Robert. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 3 SEC releases listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 3 public filings for Robert B. Nelson and found 12 differences, 2 worth asking the sponsor about: 117% of the money raised went to insiders; Robert B. Nelson is no longer listed on the Mar 5, 2026 amendment; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.